3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
37
Nivolumab
21
pembrolizumab
18
Bevacizumab
12
Cyclophosphamide
10
durvalumab
9
fludarabine
8
atezolizumab
8
Magnetic Resonance Spectroscopy
8
lenvatinib
7
Radiosurgery
7
Ipilimumab
7
Radiotherapy
6
Irinotecan
6
Oxaliplatin
5
Leucovorin
5
tremelimumab
4
toripalimab
4
tislelizumab
4
sintilimab
4
cabozantinib
4
budigalimab
4
Specimen Handling
4
Sirolimus
4
Interleukin-2
4
Fluorouracil
4
Doxorubicin
4
Capecitabine
4
130-nm albumin-bound paclitaxel
4
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Hepatocellular
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled